Welcome to LookChem.com Sign In|Join Free

CAS

  • or

10206-01-6

Post Buying Request

10206-01-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

10206-01-6 Usage

Uses

p-(1-Benzyl-2-benzimidazolyl)phenol is an inhibitor targeting the PDEδ prenyl binding site.

Check Digit Verification of cas no

The CAS Registry Mumber 10206-01-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,2,0 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 10206-01:
(7*1)+(6*0)+(5*2)+(4*0)+(3*6)+(2*0)+(1*1)=36
36 % 10 = 6
So 10206-01-6 is a valid CAS Registry Number.

10206-01-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenol

1.2 Other means of identification

Product number -
Other names 1-Benzyl-2-<4-hydroxy-phenyl>-benzimidazol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:10206-01-6 SDS

10206-01-6Relevant articles and documents

Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site

Zimmermann, Gunther,Schultz-Fademrecht, Carsten,Küchler, Philipp,Murarka, Sandip,Ismail, Shehab,Triola, Gemma,Nussbaumer, Peter,Wittinghofer, Alfred,Waldmann, Herbert

, p. 5435 - 5448 (2014/07/08)

K-Ras is one of the most frequently mutated signal transducing human oncogenes. Ras signaling activity requires correct cellular localization of the GTPase. The spatial organization of K-Ras is controlled by the prenyl binding protein PDEδ, which enhances Ras diffusion in the cytosol. Inhibition of the Ras-PDEδ interaction by small molecules impairs Ras localization and signaling. Here we describe in detail the identification and structure guided development of Ras-PDEδ inhibitors targeting the farnesyl binding pocket of PDEδ with nanomolar affinity. We report kinetic data that characterize the binding of the most potent small molecule ligands to PDEδ and prove their binding to endogenous PDEδ in cell lysates. The PDEδ inhibitors provide promising starting points for the establishment of new drug discovery programs aimed at cancers harboring oncogenic K-Ras.

BENZIMIDAZOLES FOR THE TREATMENT OF CANCER

-

Page/Page column 52; 57-58, (2014/03/22)

The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 10206-01-6